Prostate Cancer
Conditions
Keywords
Prostate cancer
Brief summary
Study will evaluate the real-world effectiveness of Depo-Eligard® after six months of treatment
Detailed description
The study will provide data on the tolerance, safety and acceptance of Depo-Eligard® (leuproreline acetate) when used in routine clinical practice. Data on efficacy parameters such as testosterone, PSA levels, symptoms and treatment failure, if available will be collected.It will reflect the way Depo-Eligard® is used in routine clinical practice and how PSA, testosterone levels, symptoms and treatment failure, are used as parameters in the treatment for Prostate Cancer. Patient data will be collected after a treatment period of six months.
Interventions
OTHERData Collection on Depo-Eligard exposure
Retrospective, Non-interventional
Sponsors
Astellas Pharma Inc
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients having been prescribed Depo-Eligard® in accordance with the terms of the marketing authorization * Patients on treatment with Depo-Eligard® for at least six months * Written consent has been obtained
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerance, Safety (Adverse drug reactions, overall evaluation of safety and tolerability) and Acceptance of Depo-Eligard® | After at least 6 months treatment with Depo-Eligard |
Secondary
| Measure | Time frame |
|---|---|
| Overall patient assessment of treatment benefit | After at least 6 months treatment with Depo-Eligard |
| Measurement of PSA and testosterone levels if available | After at least 6 months treatment with Depo-Eligard |
| Overall evaluation of efficacy | After a least 6 months treatment with Depo-Eligard |
Countries
Belgium
Outcome results
None listed